secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2026-11-06T22:18:56+00:00
Accession:  0001104659-26-123960
Event type: earnings
Sentiment:  positive
Materiality: 0.72
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Quoin Q3 2026 net loss widens to ~$4.9M as QRX003 interim Phase 2/3 data meet primary endpoint
--------------------------------------------------------------------------------

- Q3 2026 net loss ~$4.9M vs ~$3.9M a year earlier; nine-month net loss ~$15.2M vs ~$11.5M; cash, equivalents and marketable securities ~$33.2M at Sept 30, 2026.
- Interim Phase 2/3 CL-QRX003-004 data: 4 of 6 patients (66.7%) hit the IGA primary endpoint (p=0.0087 vs alpha 0.0215); key secondary p=0.0070; no treatment-related SAEs.
- Aug 28 private placement with healthcare-focused institutions for up to ~$50.0M: ~$30.8M upfront plus up to ~$19.2M from ordinary warrant exercises.
- FDA cleared the first-ever IND for QRX003 in Peeling Skin Syndrome (July 9), then granted RPD (Sept 8) and Fast Track (Sept 22); EMA added Orphan Drug status Oct 14.
- All 20 Netherton Syndrome patients expected enrolled by end-2026 with topline in Q2 2027; first company-sponsored PSS study to start before year end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926123960/0001104659-26-123960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926123960/tm2629259d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-123960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer